Effects of chemical modifications on the surface- and protein-binding properties of the light chain of human high molecular weight kininogen.
The light chain of kallikrein-cleaved human high molecular weight kininogen is solely responsible for its cofactor activity in blood clotting. Sequencing of the NH2-terminal region of the light chain reported herein identified the third kallikrein cleavage site of high molecular weight kininogen as Arg-437. The co-factor activity of high molecular weight kininogen consists of the capacity to bind to negatively charged surfaces and to factor XI or prekallikrein. Chemical modification of the histidines by either photooxidation or ethoxyformic anhydride affected the equivalent of 14-16 of 23 histidines available and resulted in over 90% loss in procoagulant activity. The modified protein had drastically reduced surface- and zinc-binding capacity, but it bound successfully to either factor XI or prekallikrein. In contrast, modification of two carboxyl groups, which led to approximately 80-90% loss of procoagulant activity, seriously compromised protein binding but left surface binding unaffected. All 3 tryptophans were modified at pH 4.0 with N-bromosuccinimide with a 70% reduction in procoagulant activity, but only 1 tryptophan was available for reaction at pH 7.35, resulting in a 50% loss in activity. Tryptophan modification at acidic pH affected protein binding but did not modify surface or zinc binding. Modification of both available tyrosine and 9 of 18 available lysine residues did not have a significant effect on the procoagulant activity of the light chain. These studies indicate that histidines participate in surface binding and that free carboxyl groups and tryptophan side chains are involved in binding of high molecular weight kininogen to other clotting factors.
D000595:Amino Acid Sequence; D001777:Blood Coagulation / Q000187:drug effects; D001974:Bromosuccinimide; D055598:Chemical Phenomena; D002621:Chemistry; D004047:Diethyl Pyrocarbonate; D005029:Ethylenediamines; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007610:Kallikreins / Q000378:metabolism; D007704:Kininogens / Q000378:metabolism* / Q000494:pharmacology; D010446:Peptide Fragments; D010777:Photochemistry; D011485:Protein Binding; D011506:Proteins / Q000378:metabolism*; D013387:Succinic Anhydrides; D013774:Tetranitromethane; D015032:Zinc / Q000378:metabolism
D005029:Ethylenediamines; D007704:Kininogens; D010446:Peptide Fragments; D011506:Proteins; D013387:Succinic Anhydrides; C031234:ethylenediamine; C031801:succinic anhydride; D007610:Kallikreins; D015032:Zinc; D013774:Tetranitromethane; D001974:Bromosuccinimide; D004047:Diethyl Pyrocarbonate